The splendor and the tyranny of JAK inhibition by Elizabeth O. Hexner

Get full text

Persistent Mixed Donor Chimerism following Double Umbilical Cord Transplantation in a Patient with T-Cell Prolymphocytic Leukemia by Ronak H. Mistry, Elizabeth O. Hexner, James K. Mangan

Get full text

The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies by Vikas Gupta, Claire Harrison, Elizabeth O. Hexner, Haifa Kathrin Al-Ali, Lynda Foltz, Michael Montgomery, William Sun, Prashanth Gopalakrishna, Hagop Kantarjian, Srdan Verstovsek

Get full text

Hodgkin lymphoma patients have an increased incidence of idiopathic acquired aplastic anemia. by Taylor Linaburg, Adam R Davis, Noelle V Frey, Muhammad R Khawaja, Daniel J Landsburg, Stephen J Schuster, Jakub Svoboda, Yimei Li, Yuliya Borovskiy, Timothy S Olson, Adam Bagg, Elizabeth O Hexner, Daria V Babushok

Get full text

RAB27B controls palmitoylation-dependent NRAS trafficking and signaling in myeloid leukemia by Jian-Gang Ren, Bowen Xing, Kaosheng Lv, Rachel A. O’Keefe, Mengfang Wu, Ruoxing Wang, Kaylyn M. Bauer, Arevik Ghazaryan, George M. Burslem, Jing Zhang, Ryan M. O’Connell, Vinodh Pillai, Elizabeth O. Hexner, Mark R. Philips, Wei Tong

Get full text

Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer by Igor Makhlin, Nicholas P. McAndrew, E. Paul Wileyto, Amy S. Clark, Robin Holmes, Lisa N. Bottalico, Clementina Mesaros, Ian A. Blair, Grace R. Jeschke, Kevin R. Fox, Susan M. Domchek, Jennifer M. Matro, Angela R. Bradbury, Michael D. Feldman, Elizabeth O. Hexner, Jacqueline F. Bromberg, Angela DeMichele

Get full text

P1023: AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM): EFFICACY AND SAFETY ANALYSES FROM THE PHASE 2 PATHFINDER STUDY WITH 2-YEAR FOLLOW-UP by Jason Gotlib, Andreas Reiter, Deepti Radia, Michael Deininger, Tracy George, Jens Panse, Alessandro Vannucchi, Uwe Platzbecker, Ivan Alvarez-Twose, Andrzej Mital, Olivier Hermine, Ingunn Dybedal, Elizabeth O. Hexner, Lambert Span, Ruben Mesa, Prithviraj Bose, Kirsten Pettit, Stephen Oh, Hui-Min Lin, Sasa Dimitrijevic, Javier Muñoz-González, Daniel J. Deangelo

Get full text

Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia by Matthew P. Connor, Neeharika Prathapa, Noelle V. Frey, Saar I. Gill, Elizabeth O. Hexner, Ximena Jordan Bruno, Catherine E. Lai, Alison W. Loren, Selina M. Luger, Andrew H. Matthews, Shannon R. McCurdy, Alexander E Perl, David L. Porter, Arlene Zeringue, Joseph H. Oved, Timothy S. Olson, Keith W. Pratz, Daria V. Babushok

Get full text

Evolving racial/ethnic disparities in AML survival in the novel therapy era by Xin Wang, Phyllis A. Gimotty, Andrew H. Matthews, Ronac Mamtani, Selina M. Luger, Elizabeth O. Hexner, Daria V. Babushok, Shannon R. McCurdy, Noelle V. Frey, Ximena Jordan Bruno, Saar Gill, Mary Ellen Martin, Vikram R. Paralkar, Ivan Maillard, David L. Porter, Alison W. Loren, Alexander E. Perl, Keith W. Pratz, Kelly D. Getz, Catherine Lai

Get full text

A phase I trial of cyclosporine for hospitalized patients with COVID-19 by Emily A. Blumberg, Julia Han Noll, Pablo Tebas, Joseph A. Fraietta, Ian Frank, Amy Marshall, Anne Chew, Elizabeth A. Veloso, Alison Carulli, Walter Rogal, Avery L. Gaymon, Aliza H. Schmidt, Tiffany Barnette, Renee Jurek, Rene Martins, Briana M. Hudson, Kalyan Chavda, Christina M. Bailey, Sarah E. Church, Hooman Noorchashm, Wei-Ting Hwang, Carl H. June, Elizabeth O. Hexner

Get full text

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial by Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Vikas Gupta, John F. DiPersio, John V. Catalano, Michael W. N. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, Mark Jones, Deanna Kornacki, Kang Sun, Hagop Kantarjian, for the COMFORT-I investigators

Get full text

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I by Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John V. Catalano, Michael W.N. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Azra Raza, Kris Vaddi, William Sun, Wei Peng, Victor Sandor, Hagop Kantarjian

Get full text

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I by Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John V. Catalano, Michael W.N. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, Kris Vaddi, Susan Erickson-Viitanen, William Sun, Victor Sandor, Hagop M. Kantarjian

Get full text

The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease by Hrishikesh K. Srinagesh, Umut Özbek, Urvi Kapoor, Francis Ayuk, Mina Aziz, Kaitlyn Ben-David, Hannah K. Choe, Zachariah DeFilipp, Aaron Etra, Stephan A. Grupp, Matthew J. Hartwell, Elizabeth O. Hexner, William J. Hogan, Alexander B. Karol, Stelios Kasikis, Carrie L. Kitko, Steven Kowalyk, Jung-Yi Lin, Hannah Major-Monfried, Stephan Mielke, Pietro Merli, George Morales, Rainer Ordemann, Michael A. Pulsipher, Muna Qayed, Pavan Reddy, Ran Reshef, Wolf Rösler, Karamjeet S. Sandhu, Tal Schechter, Jay Shah, Keith Sigel, Daniela Weber, Matthias Wölfl, Kitsada Wudhikarn, Rachel Young, John E. Levine, James L.M. Ferrara

Get full text